CRP testing market to reach $4.48 billion by 2030

The global market for C-reactive protein testing is projected to grow from $3.52 billion in 2025 to $3.7 billion in 2026, with demand rising on higher rates of inflammatory and cardiovascular disease. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region through 2030.

Why it matters: - C-reactive protein testing is becoming more important as clinicians look for faster ways to detect inflammation and assess cardiovascular risk. - The market is expanding as healthcare systems adopt more automated, high-sensitivity, and point-of-care diagnostic tools. - Rising cardiovascular disease burden is a major demand driver, with CRP testing used as a marker that can complement other risk assessments.

What happened: - The Business Research Company projected the global C-reactive protein testing market at $3.52 billion in 2025 and $3.7 billion in 2026, a 5.1% CAGR. - The market is forecast to reach $4.48 billion by 2030, implying a 4.9% CAGR from 2026 to 2030. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The company also published a free sample of the report and a full market report: the sample report and the full report.

The details: - CRP testing measures the amount of C-reactive protein in blood, which rises when the body is dealing with inflammation. - The test is used to detect inflammation tied to infections and other inflammatory conditions. - Historical growth has been supported by more inflammatory disease cases, broader clinical use of CRP tests, expanded hospital lab infrastructure, greater awareness of early diagnosis, and standardized testing kits. - The report says future growth will be driven by point-of-care inflammation testing, automated diagnostic platforms, preventive screening, high-throughput lab systems, and personalized diagnostics. - Key trends include higher use of high-sensitivity CRP assays, automated immunoassay devices, rapid inflammation diagnostics, cardiovascular risk evaluation, and laboratory workflow automation. - The report says the 2026 edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The market outlook suggests CRP testing is shifting from a basic inflammation marker toward a broader role in risk stratification and workflow-driven diagnostics. - Cardiovascular disease remains central to the growth story because the test can help clinicians identify risk earlier, before more serious events occur. - The strongest near-term opportunity appears to be in settings that need faster results and higher testing volume, including point-of-care and automated lab environments. - CDC data cited in the report showed about 919,032 cardiovascular deaths in the U.S. in 2023, or roughly one-third of all deaths, underscoring the scale of the underlying demand.

What's next: - The market is expected to keep growing steadily through 2030 as diagnostic platforms become more automated and more widely used in preventive care. - Adoption should continue to rise in cardiovascular screening and rapid inflammation testing. - Asia-Pacific’s faster growth could shift more commercial attention toward emerging healthcare markets.

The bottom line: - CRP testing is moving from a routine lab measure to a more strategic diagnostic tool, and market growth reflects that broader clinical role.